Futura Medical (LSE:FUM) has received a notice of allowance for its Eroxon® patent in China, securing protection through 2040. The approval opens a meaningful commercial pathway in a market with a high incidence of erectile dysfunction among adult men. Strengthening its intellectual property in China enhances Futura’s competitive footing and supports its strategy to secure commercial partners in the region. This latest allowance builds on patent protection already granted in Europe, Hong Kong, Taiwan, and the United States, with additional applications under review in other territories.
More about Futura Medical plc
Futura Medical plc is a consumer healthcare company focused on developing and commercializing innovative, clinically validated products for sexual health. The group’s expertise centers on topical gel formulations designed to address unmet needs in male and female sexual function. Its flagship product, Eroxon®, is an over-the-counter topical treatment for erectile dysfunction, while its pipeline includes candidates such as WSD4000, a topical therapy targeting symptoms of reduced sexual response in women.
Leave a Reply